Vertex Pharmaceuticals Inc.
- BID
422.35
- ASK
423
- 118 Units24 Units
- 07/21, 21:59:58 PM
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
6.71%
Market Cap
107.18 Bil.
P/E Ratio
29.59
Dividend Yield
0.00 %
Earnings per Share
13.58 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 422.3 G | 0 Units |
| PRICE DETERMINATION TIME | 07/21/2026 / 09:57:06 PM | |
| DAILY VOLUME (UNITS) | 14 | |
| DAILY HIGH / LOW | 422.75 | 415.1 |
| PREV. DAY'S PRICE | 421.35 | (07/20) |
| CHANGE DAY BEFORE | +0.95 | 0.23 % |
| 52 WEEK HIGH / LOW | 463.95 (07/06) | 313.15 (08/11) |
Key Figures (in EUR)
| 2023 | 2024 | 2025 | 2026e | 2027e | |
|---|---|---|---|---|---|
EARNINGS PER SHARE | 12.85 | -1.92 | 13.58 | 16.74 | 18.76 |
DIVIDENDS PER SHARE | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
DIVIDEND YIELD IN % | 0.00 % | 0.00 % | 0.00 % | - | - |
DIVIDEND GROWTH IN % | - | - | - | - | - |
PRICE - EARNINGS RATIO | 29.28 | - | 29.59 | 25.43 | 22.69 |
PRICE - BOOK RATIO | 5.96 | 6.31 | 6.17 | - | - |
PRICE - SALES RATIO | 10.77 | 9.45 | 9.69 | - | - |
PRICE - CASH FLOW RATIO | 29.96 | - | 32.21 | - | - |
Master Data
| WKN | 882807 |
| ISIN | US92532F1003 |
| SYMBOL | VX1 |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | Vertex |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | US Dollar |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | 253.81 Mil. |
| MARKET CAPITALISATION | 107.18 Bil. |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | -0.05 % | 7.68 % | 13.08 % | 11.87 % | 6.71 % | 28.81 % | 154.32 % | 8.47 % |
| HIGH | 428.85 | 463.95 | 463.95 | 463.95 | 463.95 | 489.95 | 489.95 | 463.95 |
| LOW | 411.25 | 391.30 | 356.35 | 356.35 | 313.15 | 311.50 | 151.56 | 356.35 |
Dividende
pro Aktie
Vertex does not deliver dividend information
Company profile
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.
Structured products for Vertex Pharmaceuticals Inc.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.